Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

PHASE2CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

April 26, 2023

Study Completion Date

February 21, 2024

Conditions
EczemaAtopic Dermatitis
Interventions
DRUG

Amlitelimab

Pharmaceutical form: Injection solution Route of administration: Subcutaneous

DRUG

Placebo

Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Trial Locations (103)

402

Investigative Site Number: 3202, Taichung

833

Investigative Site Number: 3201, Niao Song Qu

1036

Investigative Site Number: 2304, Budapest

1431

Investigative Site Number: 2005, Sofia

1592

Investigative Site Number: 2006, Sofia

1612

Investigative Site Number: 2003, Sofia

1784

Investigative Site Number: 2002, Sofia

2405

Investigative Site Number: 2208, Kiel

3002

Investigative Site Number: 3003, East Melbourne

3010

Investigative Site Number: 2505, Alicante

3050

Investigational Site Number: 3001, Parkville

3053

Investigative Site Number 3002, Carlton

4032

Investigative Site Number: 2303, Debrecen

5000

Investigative Site Number: 2306, Szolnok

5700

Investigative Site Number: 2305, Gyula

5800

Investigative Site Number: 2004, Pleven

6000

Investigative Site Number: 2307, Kecskemét

6003

Investigative Site Number: 2001, Stara Zagora

6720

Investigative Site Number: 2301, Szeged

8900

Investigative Site Number: 2302, Zalaegerszeg

10117

Investigative Site Number: 2203, Berlin

11217

Investigative site # 3206, Taipei

14004

Investigative Site Number: 2501, Córdoba

15827

Investigative Site Number: 2202, Blankenfelde

20251

Investigative Site Number: 2204, Hamburg

28046

Investigative Site Number: 2503, Madrid

33305

Investigative Site Number: 3203, Taoyuan District

33428

Investigative Site Number: 1006, Boca Raton

36001

Investigative Site Number: 2504, Pontevedra

40241

Investigative Site Number: 1021, Louisville

46940

Investigative Site Number: 2502, Manises

48149

Investigator Site Number: 2201, Münster

76063

Investigative site #1023, Mansfield

91054

Investigative Site Number: 2209, Erlangen

97239

Investigative Site Number: 1009, Portland

112217

Investigative site # 3206, Taipei

94538-1601

Investigative Site Number: 1018, Fremont

95816-3370

Investigative site #1022, Sacramento

33756-3424

Investigative Site Number: 1001, Clearwater

33134-2950

Investigative Site Number: 1019, Coral Gables

33176-2264

Investigative Site Number: 1007, Miami

33615-3816

Investigative Site Number: 1013, Tampa

31406-2668

Investigative Site Number: 1004, Savannah

47129-2201

Investigative Site Number: 1010, Clarksville

46250-2041

Investigative Site Number: 1015, Indianapolis

21204-7448

Investigative Site Number: 1011, Towson

01915-1666

Investigative Site Number: 1014, Beverly

48084-3536

Investigative Site Number: 1012, Troy

74136-7049

Investigative Site Number: 1005, Tulsa

97223-6683

Investigative Site Number: 1017, Portland

29621-2062

Investigative Site Number: 1003, Anderson

37130-2450

Investigative Site Number: 1008, Murfreesboro

L3P 1X2

Investigative Site Number: 1106, Markham

L2H 1H5

Investigative site #1108, Niagara Falls

K2C 3N2

Investigative Site Number: 1103, Ottawa

N2J 1C4

Investigative Site Number: 1107, Waterloo

N8W 1E6

Investigative Site Number: 1101, Windsor

741 01

Investigative Site Number: 2105, Nový Jicín

108 00

Investigative Site Number: 2102, Prague

130 00

Investigative Site Number: 2103, Prague

602 00

Investigative Site Number: 2108, Brno

284 01

Investigative Site Number: 2106, Kutná Hora

702 00

Investigative Site Number: 2104, Ostrava

270-2223

Investigative Site Number: 3103, Matsudo

080-0013

Investigative Site Number: 3114, Obihiro-Shi

890-0063

Investigative site #3108, Kagoshima

221-0825

Investigative site #3113, Yokohama

120-0034

Investigative Site Number: 3112, Adachi-Ku

Unknown

Investigative Site Number: 3115, Chuo Ku

133-0052

Investigative Site Number: 3104, Edagowa-Ku

136-0074

Investigative Site Number: 3111, Koto-Ku

108-0014

Investigative Site Number: 3107, Minato-Ku

158-0097

Investigative site #3105, Setagaya-Ku

602-0841

Investigative site #3102, Kyoto

321-0293

Investigative Site Number: 3106, Mibu-machi

060-0063

Investigative site #3101, Sapporo

583-0872

Investigative Site Number: 3109, Habikino-Shi

593-8324

Investigative Site Number: 3110, Sakaishi

30-033

Investigative Site Number: 2408, Krakow

30-510

Investigative Site Number: 2407, Krakow

31-011

Investigative Site Number: 2409, Krakow

50-088

Investigative Site Number: 2414, Wroclaw

50-368

Investigative Site Number: 2418, Wroclaw

51-685

Investigative Site Number: 2417, Wroclaw

90-349

Investigative Site Number: 2420, Lodz

Investigative site #2420, Lodz

90-127

Investigative Site Number: 2415, Lódz

00-874

Investigative Site Number: 2412, Warsaw

01-142

Investigative Site Number: 2411, Warsaw

01-192

Investigative Site Number: 2413, Warsaw

35-055

Investigative Site Number: 2401, Rzeszów

15-879

Investigative site #2419, Bialystok

Investigative site #2419, Bialystok

80-382

Investigative Site Number: 2402, Gdansk

81-384

Investigative Site Number: 2404, Gdynia

40-040

Investigative Site Number: 2405, Katowice

71-434

Investigative Site Number: 2410, Szczecin

80-592

Investigative Site Number: 2403, Gdansk

31-559

Investigative Site Number: 2406, Krakow

90-436

Investigative Site Number: 2416, Lodz

E11 1NR

Investigative Site Number: 2603, London

SE1 9RT

Investigative Site Number: 2601, London

S10 2TF

Investigative Site Number: 2602, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Kymab Limited

INDUSTRY

NCT05131477 - Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study | Biotech Hunter | Biotech Hunter